Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Saye Khoo

Showing results (211-220 of 282) with videos related to

Pageof 29
Sort By:
British Journal of Pharmacology|June 9, 2026
Identification, reliability, and validity of drug-drug interaction checkers in chronic diseases: A systematic reviewBrayden Ng Gibson, Sri Chodapuneedi, Huan Yee Koh, et al.
Antiviral Therapy|June 3, 2010
Prevalence of comedications and effect of potential drug-drug interactions in the Swiss HIV Cohort StudyCatia Marzolini, Luigia Elzi, Sara Gibbons, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 16, 2014
Cerebrospinal fluid exposure of efavirenz and its major metabolites when dosed at 400 mg and 600 mg once daily: a randomized controlled trialAlan Winston, Janaki Amin, Amanda Clarke, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 22, 2021
Total and Unbound Doravirine Concentrations and Viral Suppression in CSFJuan Tiraboschi, Sofia Scévola, Sujan Dilly Penchala, et al.
Antiviral Therapy|March 24, 2020
Genital secretion HIV RNA shedding in HIV-positive patients on ritonavir-boosted protease inhibitor monotherapy or standard combination ART: a cross-sectional sub-study from the PIVOT TrialAlejandro Arenas-Pinto, Wolfgang Stöhr, Saye Khoo, et al.
Ebiomedicine|August 20, 2015
Investigation of Efavirenz Discontinuation in Multi-ethnic Populations of HIV-positive Individuals by Genetic AnalysisNathan W Cummins, Jacqueline Neuhaus, Haitao Chu, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 20, 2023
Pharmacokinetics and Safety of Twice-daily Ritonavir-boosted Atazanavir With RifampicinKamunkhwala Gausi, Henry Mugerwa, Marco Siccardi, et al.
The Journal of Infectious Diseases|June 2, 2011
Genetic variants of ABCC10, a novel tenofovir transporter, are associated with kidney tubular dysfunctionSudeep P Pushpakom, Neill J Liptrott, Sonia Rodríguez-Nóvoa, et al.
Infectious Diseases and Therapy|February 19, 2024
Outcomes of Drug Interactions Between Antiretrovirals and Co-Medications, Including Over-the-Counter Drugs: A Real-World StudyJuan Ambrosioni, Natalia Anahí Díaz, Catia Marzolini, et al.
The Journal of Antimicrobial Chemotherapy|March 29, 2011
Integration of population pharmacokinetics and pharmacogenetics: an aid to optimal nevirapine dose selection in HIV-infected individualsAlessandro Schipani, Christoph Wyen, Tabitha Mahungu, et al.
Pageof 29

Showing results (211-220 of 282) with videos related to

Sort By:
Pageof 29
British Journal of Pharmacology|June 9, 2026
Identification, reliability, and validity of drug-drug interaction checkers in chronic diseases: A systematic reviewBrayden Ng Gibson, Sri Chodapuneedi, Huan Yee Koh, et al.
Antiviral Therapy|June 3, 2010
Prevalence of comedications and effect of potential drug-drug interactions in the Swiss HIV Cohort StudyCatia Marzolini, Luigia Elzi, Sara Gibbons, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 16, 2014
Cerebrospinal fluid exposure of efavirenz and its major metabolites when dosed at 400 mg and 600 mg once daily: a randomized controlled trialAlan Winston, Janaki Amin, Amanda Clarke, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 22, 2021
Total and Unbound Doravirine Concentrations and Viral Suppression in CSFJuan Tiraboschi, Sofia Scévola, Sujan Dilly Penchala, et al.
Antiviral Therapy|March 24, 2020
Genital secretion HIV RNA shedding in HIV-positive patients on ritonavir-boosted protease inhibitor monotherapy or standard combination ART: a cross-sectional sub-study from the PIVOT TrialAlejandro Arenas-Pinto, Wolfgang Stöhr, Saye Khoo, et al.
Ebiomedicine|August 20, 2015
Investigation of Efavirenz Discontinuation in Multi-ethnic Populations of HIV-positive Individuals by Genetic AnalysisNathan W Cummins, Jacqueline Neuhaus, Haitao Chu, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 20, 2023
Pharmacokinetics and Safety of Twice-daily Ritonavir-boosted Atazanavir With RifampicinKamunkhwala Gausi, Henry Mugerwa, Marco Siccardi, et al.
The Journal of Infectious Diseases|June 2, 2011
Genetic variants of ABCC10, a novel tenofovir transporter, are associated with kidney tubular dysfunctionSudeep P Pushpakom, Neill J Liptrott, Sonia Rodríguez-Nóvoa, et al.
Infectious Diseases and Therapy|February 19, 2024
Outcomes of Drug Interactions Between Antiretrovirals and Co-Medications, Including Over-the-Counter Drugs: A Real-World StudyJuan Ambrosioni, Natalia Anahí Díaz, Catia Marzolini, et al.
The Journal of Antimicrobial Chemotherapy|March 29, 2011
Integration of population pharmacokinetics and pharmacogenetics: an aid to optimal nevirapine dose selection in HIV-infected individualsAlessandro Schipani, Christoph Wyen, Tabitha Mahungu, et al.
Pageof 29